Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$236000.0.

  • Mereo BioPharma's Change in Account Payables rose 7784.04% to -$236000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$982000.0, marking a year-over-year decrease of 43862.07%. This contributed to the annual value of $146000.0 for FY2024, which is 11155.98% up from last year.
  • Per Mereo BioPharma's latest filing, its Change in Account Payables stood at -$236000.0 for Q3 2025, which was up 7784.04% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Change in Account Payables ranged from a high of $987000.0 in Q4 2023 and a low of -$2.3 million during Q2 2023
  • For the 3-year period, Mereo BioPharma's Change in Account Payables averaged around -$267454.5, with its median value being $127000.0 (2024).
  • Data for Mereo BioPharma's Change in Account Payables shows a peak YoY increase of 18503.94% (in 2025) and a maximum YoY decrease of 90954.36% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Mereo BioPharma's Change in Account Payables stood at $987000.0 in 2023, then dropped by 14.59% to $843000.0 in 2024, then tumbled by 128.0% to -$236000.0 in 2025.
  • Its last three reported values are -$236000.0 in Q3 2025, -$2.0 million for Q2 2025, and $362000.0 during Q1 2025.